Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 7/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401877 | 0.87 | PDE4A (0.37) | MEN1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL1542586 | 0.86 | GAA (0.47) | MEN1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL11761259 | 0.86 | GAA (0.56) | MEN1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL6572089 | 0.86 | MEN1 (0.45) | MEN1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL2163290 | 0.86 | GAA (0.47) | MEN1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL1542314 | 0.84 | GAA (0.46) | MEN1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL1541994 | 0.84 | GAA (0.46) | MEN1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL1542340 | 0.84 | GAA (0.46) | MEN1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL1391316 | 0.84 | GAA (0.57) | MEN1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL2164829 | 0.84 | GAA (0.46) | MEN1KMT2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703825-B2 | Compounds, use thereof as medicaments, and method of preparation thereof | UNIVERSITE DE LORRAINE (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20110184070-A1 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD OF PREPARATION THEREOF | UNIVERSITE HENRI POINCARE NANCY 1 (FR) | 2011-07-28 | — | — | US | disclosed |
| EP-2303837-A2 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD FOR THE PREPARATION THEREOF | Université Henri Poincaré Nancy 1 (FR) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010004231-A2 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD FOR THE PREPARATION THEREOF | UNIVERSITE HENRI POINCARE NANCY 1 (FR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184070-A1 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD OF PREPARATION THEREOF | CYP11B2, NPM1, B2M | MEN1 77/4885KMT2A 2941/4885PDE4A 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.